Tumor-immune Co-evolution in hepatocellular carcinoma and its implication for immunotherapy resistance

Zhiyuan Fang; Huayu Yang; Yilei Mao

doi:10.1016/j.iliver.2022.02.003

iLIVER 2022, 1(1): 78-80 https://doi.org/10.1016/j.iliver.2022.02.003

Short Communication |

Open Access | Issue | Published: 09 March 2022

Tumor-immune Co-evolution in hepatocellular carcinoma and its implication for immunotherapy resistance

Show Author's Information Hide Author's Information Zhiyuan Fang, Huayu Yang(

), Yilei Mao(

)

Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences (CAMS), Beijing, 100730, China

Cite this article:

Fang Z, Yang H, Mao Y. Tumor-immune Co-evolution in hepatocellular carcinoma and its implication for immunotherapy resistance. iLIVER, 2022, 1(1): 78-80. https://doi.org/10.1016/j.iliver.2022.02.003

Download citation

EndNote(RIS)

BibTeX

929

Views

Citations

Crossref

N/A

WoS

N/A

Scopus

N/A

CSCD

About this article

Publication history

Rights and permissions

Publication history

Received: 25 November 2021

Revised: 29 January 2022

Accepted: 02 February 2022

Published: 09 March 2022

Issue date: March 2022

Copyright

Rights and permissions

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by-nc-nd/4.0/)